Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis

Mitsuto Satoa Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, JapanView further author information

Yusuke Mochizukia Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, JapanView further author information

Yusuke Takahashia Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, JapanView further author information

Ken Takasonea Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, JapanView further author information

Emre Aldincb Alnylam Pharmaceuticals, Cambridge, MA, USAView further author information

Simina Ticaub Alnylam Pharmaceuticals, Cambridge, MA, USAView further author information

Gang Jiab Alnylam Pharmaceuticals, Cambridge, MA, USAView further author information

Yoshiki Sekijimaa Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, Japan;c Institute for Biomedical Sciences, Shinshu University, Nagano, JapanCorrespondence[email protected]
View further author information

show all

References

Ando Y, Adams D, Benson MD, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;29:143–155.
PubMed Web of Science ®Google Scholar
Keam SJ. Vutrisiran: first approval. Drugs. 2022;82(13):1419–1425.
PubMed Web of Science ®Google Scholar
Ticau S, Sridharan GV, Tsour S, et al. Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis. Neurology. 2021;96:e412–e422.
PubMed Web of Science ®Google Scholar
Maia LF, Maceski A, Conceição I, et al. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid. 2020;27:97–102.
PubMed Web of Science ®Google Scholar
Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785–792.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date